论文部分内容阅读
为了解、评估我国各省级药监局网站在《政府信息公开条例》生效后开展药品信息公开工作的实施情况,将国家工信部制定的政府网站绩效评估体系按药品监管信息公开特点调整后,经对我国31个省、自治区、直辖市药监局网站信息公开建设进行调查,发现目前省级药监局网站信息公开工作中普遍存在公开程度偏低、依申请公开公众参与度低和监督保障机制实施不力等问题,应从有针对性地公开信息、丰富公开途径和方式以及完善监督保障机制等方面去完善我国药品监管信息公开制度。
In order to understand and assess the implementation of the disclosure of drug information after the website of the Provincial Food and Drug Administration under the jurisdiction of the “Regulations on the Open Government Information” came into effect, the government website performance evaluation system formulated by the State Ministry of Industry and Information Technology was adjusted according to the characteristics of the openness of drug regulatory information. The investigation on the information disclosure of the website of the SFDA in 31 provinces, autonomous regions and municipalities directly under the Central Government shows that there is a low degree of publicity in the information disclosure work of the websites of the provincial-level CFDA at present. According to the low public participation on application and the implementation of the supervision and guarantee mechanism, Inadequacies and other issues should be from a targeted public information, enrich the public ways and means and improve the supervision and protection mechanisms to improve China’s drug regulatory information disclosure system.